---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000105"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:06:05.507748+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Caribou Q2 net loss $29.5M; CB-010 shows 94% ORR; cash runway into Q4 2025

## Summary
- Net loss of $29.5M for Q2 2023 versus $26.7M in Q2 2022; R&D expenses $26.5M.
- Cash, equivalents, and marketable securities $292.5M at June 30, 2023; plus $134.6M from July public offering extends runway into Q4 2025.
- CB-010 ANTLER trial: 94% ORR (15/16) and 69% CR (11/16) in dose escalation; enrolling second-line LBCL expansion.
- Pfizer invested $25M in common stock on June 30, 2023; proceeds to advance CB-011.
- Plan to share FDA feedback on CB-010 pivotal trial by YE 2023; initial dose expansion data in H1 2024.

## SEC filing metadata
- accession: 0001619856-23-000105
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000105/0001619856-23-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000105/crbu-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000105
- JSON: https://secwatch.observer/filing/0001619856-23-000105.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000105.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported second quarter of 2023 results: revenue $3.8 million.
  - Period: second quarter of 2023
  - Revenue: $3.8 million
  - Result: reported results
  source text: will be sufficient to fund its current operating plan into Q4 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.8 million for the three months ended June 30, 2023, compared to $4.2 million for the same period 2022. The decrease was primarily due to a reduction in revenue recognized under the AbbVie
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000105/0001619856-23-000105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.